Skip to content
Company Analysis

Amarin Corporation plc AMRN

A comprehensive view of key metrics, scores, and financial health for Amarin Corporation plc

Overview of Amarin Corporation plc

AMRN NCM
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech Small Cap
Amarin Corporation plc (AMRN), is a Small Cap company, in the Drug Manufacturers - General industry, last closed at $13.95, about 20.5% undervalued vs fair value, -6.8% 1Y return, ranked 1103/1145 in sector.
Metrics Rev Growth -6.6% ROE -8.2% Gross Margin 56.6%
USD 13.95
1.75%
(Delayed)
• Vol 90d: 30.9%
52-Week Range
Market Cap
$317.05M
Enterprise Value
$191.57M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 82%
Confidence: 84%
Updated: Jul 5
Top Beats

Quick Facts

Website https://www.amarincorp.com
HQ Dublin
Employees 275
Fiscal year Dec 31

Next Events

Earnings Jul 29 Estimated

Fair Value Snapshot

Bear Base Bull
$15
$17
$19
Current: $13.95 +21% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$213.6M
-6.5%%
Gross Profit
$120.9M
48.5%%
R&D Expense
$19.8M
-5.1%%
Operating Income (EBIT)
$-36.0M
53.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
9.3%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
2/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Amarin Corporation plc's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
44
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
44
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 85% Coverage
Trade-Off Triangle Visualization A ternary plot showing AMRN's balance between Growth (21.1%), Profitability (31.9%), and Safety (47.0%). Growth 21% Safety 47% Profitability 32%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

27th percentile vs peers
27
Key Signals
EPS Growth YoY 53.2% 55p Rev Growth YoY -6.6% 21p Revenue CAGR 3Y -16.7% 11p
Strengths
  • Cash Flow to Debt Ratio in top 20% of peers (3.31, 86th percentile)
  • Strong liquidity position vs peers
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

41th percentile vs peers
41
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

60th percentile vs peers
61
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Amarin Corporation plc.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$16.81
- - -
+20.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000